BPOM Indonesia and the Jordan Food and Drug Administration (JFDA) convened in Amman on May 21, 2024, with the aim of bolstering their collaboration in pharmaceutical and food supervision. The primary focus of the meeting was to streamline the registration process for Indonesian pharmaceutical products in Jordanian markets. During discussions, Wesal AL Haqaish, General Director Technical Assistant at JFDA, provided updates on the registration progress of Indonesian drug products, including forthcoming inspections for Dexa Medica’s diabetes and injection medications, alongside Biofarma’s current listing for JFDA inspection.
The meeting marked a significant step forward as BPOM and JFDA agreed to intensify their cooperation through knowledge exchange, joint inspections, and regulatory support. Noorman Effendi, Head of Cooperation and Public Relations at BPOM, emphasized their readiness to assist JFDA during inspections of Dexa Medica and Biofarma facilities. Additionally, BPOM proposed to participate as an observer in JFDA’s inspections of Indonesia’s pharmaceutical industry, aiming to foster mutual learning and best practice sharing in drug supervision.
Beyond operational collaborations, both agencies exchanged insights on international regulatory forums and harmonization efforts. Wesal AL Haqaish reiterated JFDA’s commitment to elevating regulatory standards, aligning with Global Benchmarking Tools (GBT) maturity level 3 set by the World Health Organization (WHO). Meanwhile, Noorman Effendi highlighted BPOM’s strides in obtaining WHO Listed Authority (WLA) status and its pivotal role in Codex standards for global food safety. Looking ahead, BPOM and JFDA are poised to formalize their partnership through a Memorandum of Understanding (MoU) in drug and food supervision, underscoring their joint commitment to enhancing regulatory frameworks and product safety across borders.
Reference:
